Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new XXXX marker.

@entity1 @entity788 @entity0 @entity5 @entity2 @entity787 @entity14 @entity157
BACKGROUND: The nonspecific cross-reacting antigen-50/90 (NCA-50/90) is a glycoprotein antigen which shares some antigenic determinants with @entity787 ( @entity787 ). No definite clinical value has been established for the measurement of NCA-50/90 in @entity5 @entity1 . METHODS: We established and evaluated a chemiluminescent enzyme immunoassay (CLEIA) specific for NCA-50/90 using two monoclonal antibodies. RESULTS: No significant reactivity with 4 purified related antigens including @entity787 was found in the NCA-50/90 CLEIA. Serum samples (n = 572) from @entity1 with malignant (n = 326) as well as from healthy individuals (n = 246) were analyzed by the NCA-50/90 CLEIA and by the established ACCESS @entity787 assay. The average sensitivity of NCA-50/90 for @entity5 was 40.8%, compared to 45.4% of @entity787 . Relatively high positive rates of NCA-50/90 were observed in sera from @entity1 with @entity2 (72.0%), @entity157 (62.5%), @entity788 (47.6%), @entity0 (35.6%), and @entity14 (34.5%). About 15% of @entity1 with @entity5 were positive only for NCA-50/90. The levels of NCA-50/90 and @entity787 in sera from @entity1 with @entity5 correlated only poorly. CONCLUSIONS: The present study suggests that increases in blood levels of NCA-50/90 occur in a population of @entity5 @entity1 which is different from those with elevated levels of @entity787 and that NCA-50/90 might be useful for NCA-50/90-positive, but @entity787 -negative @entity1 .
